

WOAH Priority Vaccines for AMU Reduction: Stakeholder Survey

Nov 13, 2025

Estimated completion time: 8-10 minutes

If you have questions about this survey, please
contact : f.vial@woah.org



* Required

Section 1: **About you and your organization/professional entity/ institution**

1. **Name of your organization/professional entity/ institution :** *

2. **Your name :** *

3. **Your role/position :** *

4. Which of the following best describes your organization /professional entity/ institution 's primary role? (Select one) *

- ☐ Research funding organization
- ☐ Research consortium/academic institution
- ☐ Veterinary pharmaceutical/vaccine manufacturer
- ☐ Food producing industry (livestock/aquaculture producer or producer organization)
- ☐ Other

5. Geographic scope of your organization/professional entity/ institution's activities: (Select all that apply) *

- ☐ Global
- ☐ Africa
- ☐ Americas
- ☐ Asia and Pacific
- ☐ Europe
- ☐ Middle East

6. Which animal production sectors do you work with? (Select all that apply) *

- ☐ Pigs
- ☐ Chickens (broilers and/or layers)
- ☐ Fish/aquaculture

Section 2: **Awareness and impact of previous WOAH priority disease lists**

7. **Were you aware of WOAH's priority disease list published in 2015 (pigs, chickens, fish) ? ***

- ☐ Yes
- ☐ No

8. **If you answered "Yes", how did you first learn about these lists? (Select all that apply) ***

- ☐ WOAH website or publications
- ☐ Scientific literature/peer-reviewed journals
- ☐ Industry conferences or meetings
- ☐ Professional networks/colleagues
- ☐ Funding organization communications
- ☐ Research consortium or collaborative network
- ☐ Other

9. **To what extent did the 2015 priority disease list influence your organization's decisions or activities?**

	No influence	Somewhat influenced	Significantly influenced
Research priority setting	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Funding allocation decisions	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Vaccine R&D investment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Manufacturing/ scale-up decisions	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Advocacy efforts	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Industry recommendations/guidelines	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

10. **Can you provide a specific example of how your organization used or referenced the 2015 priority list? (optional)**

11. **What factors limited the use or impact of the 2015 list for your organization? (Select all that apply) ***

- ☐ Not aware of the lists
- ☐ Difficult to access or find the reports
- ☐ Lacked actionable details (e.g., vaccine specifications, TPPs)
- ☐ Priorities did not align with our geographic/sector focus
- ☐ Insufficient evidence or data to support the prioritization
- ☐ No clear pathway for implementation or follow-up
- ☐ No factors - the lists were useful as published
- ☐ Other

Section 3 : Future engagement with the updated priority list (2026-2030)

12. **WOAH will update the list with focus on pigs, chickens, and fish. The expert group will identify a "Top 6" priority diseases (2 per sector) and develop target product profiles (TPPs) for new or improved vaccines, plus analyze barriers to uptake for existing vaccines. How valuable would the following outputs be to your organization? ***

	Not valuable	Somewhat valuable	Extremely valuable
Updated priority disease list (Top 6)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Vaccine target product profiles (TPPs) for new/improved vaccines	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Analysis of barriers and levers to vaccine uptake for existing vaccines	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Communication, dissemination and exploitation plan for the 3 outputs above	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

13. **Would your organization be interested in reviewing and providing feedback on draft outputs during the expert group process (2025-2026) ***

- ☐ Yes, definitely interested
- ☐ Possibly interested - depends on timing/capacity
- ☐ No, but we would like to receive the final outputs
- ☐ No

14. **If you answered "Yes" or "Possibly", which outputs would you be most interested in reviewing?** (Select all that apply) *

- ☐ Updated priority disease lists
- ☐ Vaccine target product profiles (TPPs)
- ☐ Barriers/levers to uptake analysis
- ☐ Communication, Dissemination, Exploitation plan
- ☐ All of the above

15. **How would you prefer to be informed about the findings from this work?** (Select all that apply) *

- ☐ Email notifications from WOAHA
- ☐ WOAHA website/publications page
- ☐ Webinars or virtual presentations
- ☐ Direct outreach from WOAHA to our organization
- ☐ Through industry associations or networks
- ☐ Other

16. **Who in your organization should WOAHA engage with to present findings and discuss potential alignment around R&D priorities, manufacturing, or implementation? Please provide name and role/title.**

17. Beyond disseminating findings, how could WOA best support your organization to act on the updated priority list and TPPs?

Please select at most 3 options.

- ☐ Facilitate connections with other stakeholders (funders, developers, manufacturers, etc.)
- ☐ Provide technical support on vaccine implementation
- ☐ Convene stakeholder workshops or partnerships
- ☐ Support advocacy for increased funding/investment
- ☐ Develop communication materials tailored to your stakeholder group
- ☐ Provide regular progress updates on vaccine development/uptake
- ☐ Support regulatory harmonization efforts
- ☐ Other

18. What specific actions might your organization take in response to the updated priority list and TPPs over the next 5 years? (Select all that apply) *

- ☐ Adjust research funding priorities
- ☐ Initiate or expand vaccine R&D programs
- ☐ Invest in manufacturing capacity/scale-up
- ☐ Incorporate priorities into industry recommendations/guidelines
- ☐ Advocate with policymakers for supportive policies/incentives
- ☐ Collaborate with other organizations on priority vaccines
- ☐ No specific actions anticipated
- ☐ Other

Section 4 : **Additional Insights**

19. **What are the most significant barriers your organization faces in advancing animal vaccines that reduce antimicrobial use? ***

20. **Are there specific diseases in pigs, chickens, or fish that you believe should be prioritized but might not be widely recognized?**

21. **Any additional comments or suggestions for WOA's work on prioritizing vaccines to reduce antimicrobial use?**

This content is neither created nor endorsed by Microsoft. The data you submit will be sent to the form owner.



Microsoft Forms